載入...
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
B-RAF is the most frequently mutated protein kinase in human cancers.1 The finding that oncogenic mutations in BRAF are common in melanoma2 followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway3 offered hope that inhibition of B-RAF kinase activity could benefit me...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2010
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2948082/ https://ncbi.nlm.nih.gov/pubmed/20823850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09454 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|